Annual report pursuant to Section 13 and 15(d)

STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS??? EQUITY (DEFICIT)

v3.22.0.1
STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common stocks
Treasury stocks
Additional paid-in capital
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2018 60,813,980        
Beginning balance at Dec. 31, 2018 $ 48,001        
Increase (Decrease) in Temporary Equity [Roll Forward]          
Issuance of Series F preferred stocks, net of issuance cost (in shares) 12,876,360        
Issuance of Series F preferred stocks, net of issuance cost $ 29,692        
Accretion of preferred stocks to redemption value $ 2,007        
Ending balance (in shares) at Dec. 31, 2019 73,690,340        
Ending balance at Dec. 31, 2019 $ 79,700        
Beginning balance (in shares) at Dec. 31, 2018   15,754,951 1,914,328    
Balance at Dec. 31, 2018 (33,923) $ 2 $ (1,629) $ 4,588 $ (36,884)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Accretion of preferred stocks to redemption value (2,007)     (2,007)  
Stock-based compensation 378     378  
Stock options exercised (in shares)   214,309      
Stock options exercised 99     99  
Net loss (7,334)       (7,334)
Ending balance (in shares) at Dec. 31, 2019   15,969,260 1,914,328    
Balance at Dec. 31, 2019 (42,787) $ 2 $ (1,629) 3,058 (44,218)
Increase (Decrease) in Temporary Equity [Roll Forward]          
Accretion of preferred stocks to redemption value $ 7,297        
Ending balance (in shares) at Dec. 31, 2020 73,690,340        
Ending balance at Dec. 31, 2020 [1] $ 86,997        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Accretion of preferred stocks to redemption value (7,297)     (4,214) (3,083)
Capital contribution 504     504  
Stock-based compensation 584     584  
Stock options exercised (in shares)   306,349      
Stock options exercised 78     78  
Net loss (812)       (812)
Ending balance (in shares) at Dec. 31, 2020   16,275,609 1,914,328    
Balance at Dec. 31, 2020 (49,730) $ 2 $ (1,629) 10 (48,113)
Increase (Decrease) in Temporary Equity [Roll Forward]          
Accretion of preferred stocks to redemption value $ 77,063        
Conversion of redeemable convertible preferred stock into common stock (in shares) (73,690,340)        
Conversion of redeemable convertible preferred stock into common stock $ (164,060)        
Ending balance (in shares) at Dec. 31, 2021 0        
Ending balance at Dec. 31, 2021 [1] $ 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Accretion of preferred stocks to redemption value (77,063)     (4,172) (72,891)
Conversion of redeemable convertible preferred stock into common stock (in shares)   73,690,340      
Conversion of redeemable convertible preferred stock into common stock 164,060 $ 7   164,053  
Reverse recapitalization, net (in shares)   25,154,340 (1,914,328)    
Reverse recapitalization, net 126,026 $ 3 $ 1,629 124,394  
Conversion of Legacy Innovid warrants ( in shares)   507,994      
Conversion of Legacy Innovid Warrants 5,080     5,080  
Warrant exercised (in shares) [2]   132,392      
Stock-based compensation 3,273     3,273  
Stock options exercised (in shares)   3,256,705      
Stock options exercised 1,081     1,081  
Net loss (11,472)       (11,472)
Ending balance (in shares) at Dec. 31, 2021   119,017,380 0    
Balance at Dec. 31, 2021 $ 161,255 $ 12 $ 0 $ 293,719 $ (132,476)
[1] Prior period results have been adjusted to reflect the exchange of Innovid Inc’s common stock for Innovid Corp’s common stock at an exchange ratio of approximately 1.337 as a result of the Transaction. See Note 5, “Transaction and Business Combination” in the notes to the consolidated financial statements for further details.
[2] The warrant was exercised in November 2021 and was net share settled.